Efficacy and safety of imipenem/cilastatin/relebactam (IMI/CS/REL): a meta-analysis of randomized controlled clinical trials
Abstract Background Relebactam is a new inhibitor of class A and class C β-lactamases. The FDA has approved combining IMI/CS/REL to treat some infectious diseases. This study systematically reviews the efficacy and safety of IMI/CS/REL based on existing clinical trials so as to provide a reference f...
Spremljeno u:
| Glavni autori: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMC
2025-09-01
|
| Serija: | BMC Infectious Diseases |
| Teme: | |
| Online pristup: | https://doi.org/10.1186/s12879-025-11499-w |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|